Clinical outcomes and predictive value of programmed cell death-ligand 1 expression in response to anti-programmed cell death 1/ligand 1 antibodies in non-small cell lung cancer patients with performance status 2 or greater-Reference-Cited by-同舟云学术

Clinical outcomes and predictive value of programmed cell death-ligand 1 expression in response to anti-programmed cell death 1/ligand 1 antibodies in non-small cell lung cancer patients with performance status 2 or greater

Published:2020-09-23 Issue:1 Volume:26 Page:78-86
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Jodai Takayuki,Saruwatari Koichi,Ikeda Tokunori,Moriyama Eiji,Kashiwabara Kosuke,Shingu Naoki,Iyonaga Kazuhiro,Inaba Megumi,Ajishi Yusuke,Honda Chiharu,Hirosako Susumu,Maruyama Hirotaka,Kakiuchi Yosuke,Eida Hirofumi,Tomita Yusuke,Saeki Sho,Ichiyasu Hidenori,Sakagami Takuro

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

https://link.springer.com/content/pdf/10.1007/s10147-020-01789-5.pdf

Reference28 articles.

1. Assi HI, Kamphorst AO, Moukalled NM et al (2018) Immune checkpoint inhibitors in advanced non-small cell lung cancer. Cancer 124(2):248–261. https://doi.org/10.1002/cncr.31105

2. Rittmeyer A, Barlesi F, Waterkamp D et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet (London, England) 389(10066):255–265. https://doi.org/10.1016/s0140-6736(16)32517-x

3. Herbst RS, Baas P, Kim DW et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet (London, England) 387(10027):1540–1550. https://doi.org/10.1016/s0140-6736(15)01281-7

4. Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. New Eng J Med 373(2):123–135. https://doi.org/10.1056/NEJMoa1504627

5. Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. New Eng J Med 373(17):1627–1639. https://doi.org/10.1056/NEJMoa1507643

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy;Current Oncology;2023-05-26

2. A Bayesian network analysis of immunotherapy and taxane chemotherapy as second- or later-line treatments in non-small cell lung cancer;Medicine;2022-11-11

3. Cancer evolution: Special focus on the immune aspect of cancer;Seminars in Cancer Biology;2022-11

4. Anti–PD-1 Monotherapy for Advanced NSCLC Patients with Older Age or Those with Poor Performance Status;OncoTargets and Therapy;2021-03